Enrico M. Novelli

Enrico M. Novelli

Hematology

3601 Fifth Ave, Falk Building, 3rd Floor
Pittsburgh, PA 15213

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 100 publications

Factors associated with hemoglobin response to hydroxyurea in patients with sickle cell disease.

Factors associated with hemoglobin response to hydroxyurea in patients with sickle cell disease.

Journal: Blood. Red cells & iron

Published: July 29, 2026

Heme-mediated Tau phosphorylation drives neurocognitive responses in sickle cell disease.

Heme-mediated Tau phosphorylation drives neurocognitive responses in sickle cell disease.

Journal: Blood. Red cells & iron

Published: April 20, 2026

Design, rationale, and baseline patient characteristics for the Sickle Cell Disease and CardiovAscular Risk - Red cell Exchange (SCD-CARRE) trial.

Design, rationale, and baseline patient characteristics for the Sickle Cell Disease and CardiovAscular Risk - Red cell Exchange (SCD-CARRE) trial.

Journal: American heart journal

Published: April 16, 2026

The CYB5R3 T117S Missense Variant is Associated with Attenuated Riociguat Efficacy in Sickle Cell Disease.

The CYB5R3 T117S Missense Variant is Associated with Attenuated Riociguat Efficacy in Sickle Cell Disease.

Journal: Blood

Published: March 31, 2026

Newborn Screening Results for Sickle Cell Disease from the ASH Consortium on Newborn Screening in Africa (CONSA).

Newborn Screening Results for Sickle Cell Disease from the ASH Consortium on Newborn Screening in Africa (CONSA).

Journal: Blood advances

Published: January 21, 2026

Newborn screening results for sickle cell disease from the ASH Consortium on Newborn Screening in Africa (CONSA).

Newborn screening results for sickle cell disease from the ASH Consortium on Newborn Screening in Africa (CONSA).

Journal: Blood advances

Published: January 21, 2026

The paradox of HbSC disease-Not so benign after all.

The paradox of HbSC disease-Not so benign after all.

Journal: Seminars in hematology

Published: January 16, 2026

Hydroxyurea reduces hyper-adhesion measured by a VLA-4 targeting PET tracer in sickle transgenic Townes mice.

Hydroxyurea reduces hyper-adhesion measured by a VLA-4 targeting PET tracer in sickle transgenic Townes mice.

Journal: Blood advances

Published: December 23, 2025

Advancing approaches to identify young children at risk for post-discharge mortality: Protocol for a prospective observational cohort study in Western Kenya.

Advancing approaches to identify young children at risk for post-discharge mortality: Protocol for a prospective observational cohort study in Western Kenya.

Journal: BMJ paediatrics open

Published: October 14, 2025

Genotype Differences and Hydroxyurea Utilization Among Adults With Moderate to Severe Sickle Cell Disease.

Genotype Differences and Hydroxyurea Utilization Among Adults With Moderate to Severe Sickle Cell Disease.

Journal: Pharmacotherapy

Published: October 12, 2025

Real-world use of pharmacologic therapy and chronic blood transfusion in sickle cell disease, 2014-2021.

Real-world use of pharmacologic therapy and chronic blood transfusion in sickle cell disease, 2014-2021.

Journal: Annals of hematology

Published: September 30, 2025

Tebapivat Improves Red Cell Deformability and Decreases Sickling in Patients With Sickle Cell Disease: A Phase 1 Trial Substudy.

Tebapivat Improves Red Cell Deformability and Decreases Sickling in Patients With Sickle Cell Disease: A Phase 1 Trial Substudy.

Journal: European journal of haematology

Published: September 22, 2025

Showing 1-12 of 100

Last Updated: 09/26/2026